Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9116623 | 0.80 | — | — | |
| SCHEMBL317183 | 0.76 | — | — | |
| SCHEMBL312355 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL9330078 | 0.74 | TSHR (0.32) | SMN1; SMN2TSHRKMT2A | |
| SCHEMBL21931937 | 0.74 | — | — | |
| Perfluorotoluene SCHEMBL308464 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRMEN1KMT2A | |
| Perfluorotoluene SCHEMBL28760715 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL3168128 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRMEN1KMT2A | |
| Perfluorotoluene SCHEMBL28273865 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL6130585 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0251041-B1 | PROCESS FOR PREPARING 2,3,5,6-TETRAFLUOROBENZOIC ACID AND THE COMPOUNDS 2,3,5,6-TETRACHLORO-4-TRIFLUOROMETHYLBENZOYL CHLORIDE AND 2,3,5,6-TETRAFLUORO-4-TRIFLUOROMETHYLBENZOYL FLUORIDE | BAYER AG (DE) | 1989-11-08 | — | — | EP | claimed |
| EP-0251041-A1 | Process for preparing 2,3,5,6-tetrafluorobenzoic acid and the compounds 2,3,5,6-tetrachloro-4-trifluoromethylbenzoyl chloride and 2,3,5,6-tetrafluoro-4-trifluoromethylbenzoyl fluoride | BAYER AG (DE) | 1988-01-07 | — | — | EP | claimed |
| US-9343777-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-05-17 | — | — | US | disclosed |
| US-9252457-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-8697295-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-04-15 | — | — | US | disclosed |
| US-20130337318-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-12-19 | — | — | US | disclosed |
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120231330-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-1790640-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CBR1, NR0B1, CNKSR1 | SMN1; SMN2 2845/4885TSHR 89/4885MEN1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.